Dr. Craig Binnie has more than 20 years of experience in the design and management of clinical drug development programs. Prior to joining PlantForm in 2014, Binnie held leadership roles in the R&D groups of Pfizer (UK) Ltd. and Cangene Corporation, and diverse director-level positions in YM BioSciences, Transition Therapeutics, Trillium Therapeutics and Induce Biologics Inc.
Dr. Binnie has overseen GMP manufacturing, non-clinical and early clinical studies required for regulatory submissions in Canada, the United States and Europe. He has a PhD from the University of Glasgow, and performed post-doctoral studies at Harvard University and the University of Glasgow.